OPKO Health, Inc. (NYSE:OPK), a multi-national biopharmaceutical and diagnostics company, today reported operating and financial results for its third quarter ended September 30, 2014.
Business Highlights
•Rayaldee Meets Primary Endpoints in Both Pivotal Phase 3 Trials; NDA Submission planned for Q4 2014: OPKO announced successful top-line results from both of its pivotal Phase 3 trials with Rayaldee.
Help employers find you! Check out all the jobs and post your resume.
